Literature DB >> 11298122

A defect in bone marrow derived dendritic cell maturation in the nonobesediabetic mouse.

J Strid1, L Lopes, J Marcinkiewicz, L Petrovska, B Nowak, B M Chain, T Lund.   

Abstract

The pathogenesis of diabetes in the nonobese diabetic (NOD) mouse is characterized by a selective destruction of the insulin-producing beta-cells in the islets of Langerhans mediated by autoreactive T cells. The function of T cells is controlled by dendritic cells (DC), which are not only the most potent activators of naïve T cells, but also contribute significantly to the establishment of central and peripheral tolerance. In this study, we demonstrate that the NOD mouse (H2: K(d), Ag(7), E*, D(b)) shows selective phenotypic and functional abnormalities in DC derived from bone marrow progeny cells in response to GM-CSF (DC(NOD)). NOD DC, in contrast to CBA DC, have very low levels of intracellular I-A molecules and cell surface expression of MHC class II, CD80, CD86 and CD40 but normal beta 2-microglobulin expression. Incubation with the strong inflammatory stimulus of LPS and IFN-gamma does not increase class II MHC, CD80 or CD86, but upregulates the level of CD40. The genetic defect observed in the DC(NOD) does not map to the MHC, because the DC from the MHC congenic NOD.H2(h4) mouse (H2: K(k), A(k), E(k), D(k)) shares the cell surface phenotype of the DC(NOD). DC from these NOD.H2(h4) also fail to present HEL or the appropriate HEL-peptide to an antigen-specific T cell hybridoma. However all the DC irrespective of origin were able to produce TNF-alpha, IL-6, low levels of IL-12(p70) and NO in response to LPS plus IFN-gamma. A gene or genes specific to the NOD strain, but outside the MHC region, therefore must regulate the differentiation of DC in response to GM-CSF. This defect may contribute to the complex genetic aetiology of the multifactorial autoimmune phenotype of the NOD strain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298122      PMCID: PMC1906008          DOI: 10.1046/j.1365-2249.2001.01473.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

Review 3.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

4.  Splenic dendritic cells from the non-obese diabetic mouse induce a prolonged proliferation of syngeneic T cells. A role for an impaired apoptosis of NOD T cells?

Authors:  K Radosevic; K M Casteels; C Mathieu; W Van Ewijk; H A Drexhage; P J Leenen
Journal:  J Autoimmun       Date:  1999-12       Impact factor: 7.094

5.  Immunotherapy of NOD mice with bone marrow-derived dendritic cells.

Authors:  M Feili-Hariri; X Dong; S M Alber; S C Watkins; R D Salter; P A Morel
Journal:  Diabetes       Date:  1999-12       Impact factor: 9.461

6.  Immunobiology of DC in NOD mice.

Authors:  P A Morel; A C Vasquez; M Feili-Hariri
Journal:  J Leukoc Biol       Date:  1999-08       Impact factor: 4.962

7.  Cutting edge: homologous recombination of the MHC class I K region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice.

Authors:  M Hattori; E Yamato; N Itoh; H Senpuku; T Fujisawa; M Yoshino; M Fukuda; E Matsumoto; T Toyonaga; I Nakagawa; M Petruzzelli; A McMurray; H Weiner; T Sagai; K Moriwaki; T Shiroishi; R Maron; T Lund
Journal:  J Immunol       Date:  1999-08-15       Impact factor: 5.422

8.  Transfer of dendritic cells (DC) ex vivo stimulated with interferon-gamma (IFN-gamma) down-modulates autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  M Shinomiya; S M Fazle Akbar; H Shinomiya; M Onji
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

9.  The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice.

Authors:  H S Jun; C S Yoon; L Zbytnuik; N van Rooijen; J W Yoon
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

10.  Analysis of the role of variation of major histocompatibility complex class II expression on nonobese diabetic (NOD) peripheral T cell response.

Authors:  W M Ridgway; H Ito; M Fassò; C Yu; C G Fathman
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  22 in total

Review 1.  Dendritic cell immunotherapy for autoimmune diabetes.

Authors:  Maryam Feili-Hariri; Rafael R Flores; A Cecilia Vasquez; Penelope A Morel
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 2.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

Review 3.  Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease.

Authors:  John P Driver; David V Serreze; Yi-Guang Chen
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

Review 4.  Role of regulatory invariant CD1d-restricted natural killer T-cells in protection against type 1 diabetes.

Authors:  Shabbir Hussain; Melany Wagner; Dalam Ly; Terry L Delovitch
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells.

Authors:  C Haase; L Yu; G Eisenbarth; H Markholst
Journal:  Clin Exp Immunol       Date:  2010-02-18       Impact factor: 4.330

6.  Multiple immuno-regulatory defects in type-1 diabetes.

Authors:  Anjli Kukreja; Giulia Cost; John Marker; Chenhui Zhang; Zhong Sun; Karen Lin-Su; Svetlana Ten; Maureen Sanz; Mark Exley; Brian Wilson; Steven Porcelli; Noel Maclaren
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

7.  Exaggerated Increases in Microglia Proliferation, Brain Inflammatory Response and Sickness Behaviour upon Lipopolysaccharide Stimulation in Non-Obese Diabetic Mice.

Authors:  Barry McGuiness; Sinead M Gibney; Wouter Beumer; Marjan A Versnel; Inge Sillaber; Andrew Harkin; Hemmo A Drexhage
Journal:  Neuroimmunomodulation       Date:  2016-08-17       Impact factor: 2.492

8.  Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells.

Authors:  Thomas Enzler; Silke Gillessen; Michael Dougan; James P Allison; Donna Neuberg; Darryl A Oble; Martin Mihm; Glenn Dranoff
Journal:  Blood       Date:  2007-05-04       Impact factor: 22.113

9.  Passive transfer of flt-3L-derived dendritic cells delays diabetes development in NOD mice and associates with early production of interleukin (IL)-4 and IL-10 in the spleen of recipient mice.

Authors:  J Morin; B Faideau; M-C Gagnerault; F Lepault; C Boitard; S Boudaly
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 10.  Immunomodulation of autoimmune diabetes by dendritic cells.

Authors:  Klaus Pechhold; Kerstin Koczwara
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.